Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Catalent Pharma Solutions, a provider of packaging, development and manufacturing services for pharmaceutical, biotechnology and consumer healthcare companies, has appointed two new directors Melvin Booth and Arthur Higgins to its board. Mr Booth's appointment is effective immediately, while Mr Higgins is expected to join the board effective August 1, 2010.
Subscribe to our email newsletter
Prior to joining Catalent Pharma Mr Booth worked as president and chief operating officer of Medimmune, from 1998 through his retirement in 2003, and as a director from 1998 through 2005.
Mr Booth served as lead director for Millipore until its recent acquisition by Merck and currently serves on the board of Ventria BioScience, as chairman of the board for PRA International, and as a strategic advisor in life sciences for Genstar Capital. Mr Booth is also expected to join Catalent’s audit committee.
Before joining Catalent Pharma Mr Higgins served as chairman of the Bayer HealthCare executive committee from 2004 to 2010, and as chairman of the board of management of Bayer HealthCare from 2006 to 2010.
John Chiminski, president and CEO of Catalent, said: “We are very pleased to have both Mel and Art join Catalent’s board of directors. Their pharmaceutical and biotechnology market experience is expected to be an asset to Catalent as we accelerate our growth.”